anonymous
Guest
anonymous
Guest
Bottom line....Libre 3 has had its shake down run in Germany for a year and a half to eliminate the bugs. Now that this limited release is done Libre 3 is ready for general wide release. G7 was just approved by the EU a few months back and does not have FDA approval. The G7 is a year or more behind Libre 3 in terms of product maturity. And, as mentioned by others, Abbott has the money and has spent 1/2 a billion bucks on a state-of-the-art sensor manufacturing plant. DexCom is way behind and in trouble....
So what? It’s cool technology that everybody wants. At the end of the day, work for the best company. Hands down, it’s Dexcom. Being treated like an adult in a smaller, entrepreneurial setting beats the herd culture at big pharma any day.